Thursday, ESSA Pharma Inc (NASDAQ:EPIX) shares closed 22.6% lower at $6.80. According to data from Benzinga Pro, session volume stands at 447.615K compared to the average volume (100 days) of 132.003K.
The company announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten (formerly EPI-7386) in combination with enzalutamide at the 2024 ASCO Genitourinary Cancers Symposium.
Masofaniten is a first-in-class N-terminal domain androgen receptor inhibitor that suppresses androgen activity through a novel mechanism of action and is being ...